Human leukocyte antigen G (HLA-G) belongs to the non-classic major histocompatibility complex class Ib (MHC Ib) molecule, including membrane and soluble isoforms. HLA-G regulates the function of various immune cells through corresponding receptors. It is one of the important immunological mechanisms of maternal-fetal tolerance and tumor immune escape. Non-small cell lung cancer (NSCLC) patients account for the highest proportion of lung cancer patients and have poor prognoses. Studies have shown that the gene polymorphism and expression level of HLA-G is closely related to the occurrence and development of NSCLC. It is suggested that HLA-G can be used as a potential biomarker for the early diagnosis, subtype differentiation, treatment, and prognosis of NSCLC patients. HLA-G has clinical value as an auxiliary diagnostic basis. An in-depth study of its mechanism can provide new strategies for the diagnosis and treatment of NSCLC patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Pulmonary sarcomatoid carcinoma coexisting with tuberculosis: a case report and literature review.
Front Oncol
January 2025
Department of Oncology, Guangzhou Chest Hospital, Guangzhou, China.
Pulmonary sarcomatoid carcinoma (PSC) is a rare non-small-cell lung cancer with sarcomatous components or sarcomatoid differentiation, high degree of malignancy, and insensitivity to chemotherapy or radiotherapy. The management of PSC coexisting with tuberculosis (TB) poses a greater challenge, as it necessitates concurrent administration of both anti-TB and anti-neoplastic therapies. The efficacy of anti-PD-1 immunotherapy in non-small-cell lung cancer is promising, but its safety in patients with co-existent TB remains uncertain.
View Article and Find Full Text PDFCancer-associated fibroblast-derived exosomal FAM83F regulates KIF23 expression to promote the malignant progression and reduce radiosensitivity in non-small cell lung cancer.
Cytotechnology
April 2025
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing Cancer Institute, Chongqing Cancer Hospital, Chongqing University Cancer Hospital, Chongqing, 400030 China.
Unlabelled: Cancer-associated fibroblasts (CAFs) have been shown to play a crucial role in the progression of non-small cell lung cancer (NSCLC). Exosomes derived from CAFs have emerged as important mediators of intercellular communication in the tumor microenvironment, contributing to cancer progression. Therefore, it is essential to further investigate the mechanisms by which CAF-derived exosomes regulate NSCLC.
View Article and Find Full Text PDFClinical efficacy and safety evaluation of traditional Chinese medicine for nourishing yin and Replenishing qi in combination with PD-1/PD-L1 inhibitors in the treatment of NSCLC patients: a meta-analysis.
Toxicol Res (Camb)
February 2025
Respiratory Medicine, The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, 71 Baoshan North Road, Yunyan District, Guiyang Guizhou 550001, China.
To examine the therapeutic effectiveness and safety of traditional Chinese medicine in conjunction with PD-1/PD-L1 inhibitors for nourishing yin and replenishing qi in patients with non-small cell lung cancer. A systematic search was conducted across seven electronic databases, namely PubMed, Cochrane Library, Excerpt Medica Database, Web of Science, Chinese Biomedical Literature Database, China National Knowledge Infrastructure, and Wan-fang Database, to identify eligible studies from 2,000 to 2,023. This study includes a total of 14 randomized controlled clinical trials, with 514 patients in the TCM combo therapy group and 506 patients in the control group.
View Article and Find Full Text PDFAfatinib and Necitumumab in -Mutant NSCLC with Acquired Resistance to Tyrosine Kinase Inhibitors.
JTO Clin Res Rep
February 2025
Department of Medicine, Division of Oncology, Stanford University, Stanford, California.
Introduction: Although tyrosine kinase inhibitors (TKIs) are effective against NSCLC harboring sensitizing gene mutations, acquired resistance is inevitable. Preclinical studies suggest that combining EGFR TKI and monoclonal antibody therapies may have activity in mutated NSCLC that has progressed on TKI therapy alone. Therefore, we prospectively evaluated afatinib plus necitumumab in patients with mutated NSCLC.
View Article and Find Full Text PDFCorrelation of P53 expression and epithelial-mesenchymal transition in non-small cell lung cancer.
Indian J Pathol Microbiol
January 2025
Department of Pathology, Beijing Geriatric Hospital, Beijing, China.
Background: Investigation of a potential prognostic marker expressed in non-small cell lung cancer (NSCLC) can help patients benefit from new target therapeuticmodalities.
Aims: To study the expression and correlation of P53 protein and epithelial-mesenchymal transition (EMT) related makers in NSCLC.
Materials And Methods: 32 cases were selected for immunohistochemistry analysis to evaluate the expression of P53 and EMT-related makers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!